Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.62 |
| ▸ | AGXT | P21549 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28797389 | 1.00 | ADRA2C (0.62) | ADRA2CAGXTHTR3AKDM4EGAA | |
| SCHEMBL6851591 | 1.00 | ADRA2C (0.62) | ADRA2CAGXTHTR3AKDM4EGAA | |
| SCHEMBL11955062 | 0.86 | ADRA2C (0.61) | ADRA2CAGXTHTR3AKDM4EGAA | |
| SCHEMBL8050667 | 0.82 | CYP3A4 (0.50) | AGXTKDM4EMAPTMAPK1HTT | |
| SCHEMBL5654750 | 0.82 | CYP3A4 (0.50) | AGXTKDM4EMAPTMAPK1HTT | |
| SCHEMBL23709488 | 0.81 | ADRA2C (0.54) | ADRA2CAGXTHTR3AKDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL6689154 | 0.81 | CYP3A4 (0.49) | AGXTKDM4EMAPTMAPK1HTT | |
| Hydrochloric Acid SCHEMBL3975530 | 0.81 | CYP3A4 (0.49) | AGXTKDM4EMAPTMAPK1HTT | |
| Hydrochloric Acid SCHEMBL6851464 | 0.81 | CYP3A4 (0.49) | AGXTKDM4EMAPTMAPK1HTT | |
| SCHEMBL15969523 | 0.80 | LMNA (0.50) | GAAMAPTMAPK1RECQLHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| CN-102459234-B | Substituted benzotriazines and quinoxalines as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LTD. (GB) | 2014-10-15 | — | — | CN | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| CN-102459234-A | Substituted benzotriazines and quinoxalines as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LTD | 2012-05-16 | — | — | CN | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | CDK1, CDK2, CDK6 | ADRA2C 2987/4885AGXT 3572/4885HTR3A 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.